Aspirus Regional Cancer Center

Cancer Clinical Trials

This is a current listing of active clinical trials at the Aspirus Regional Cancer Center. From this list you can select a specific cancer that you are interested in (for example, breast or colon cancer) and then review the clinical trials that are active at the Aspirus Regional Cancer Center for that specific disease.

Bladder

Trial Name: A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab To Gemcitabine, Cisplatin, and Placebo in Patients with Advanced Transitional Cell Carcinoma.

Protocol ID: CALGB 90601

Eligibility:

  • Patients must have histologically or cytologically documented metastatic or unresectable transitional cell (urothelial) carcinoma of the urinary tract (renal pelvis, ureter, bladder, prostate, or urethral), with metastatic or locally advanced disease.  Patients must not be candidates for potentially curative surgery or radiotherapy.
  • Patients must not have received combination systemic chemotherapy for metastatic disease.
  • No prior treatment with bevacizumab or other angiogenesis inhibitors.
  • No known brain metastases.
  • No current congestive heart failure.
  • No serious or non-healing wound, ulcer or bone fracture.
  • Patients that are pregnant or nursing are not eligible.
  • Patients with known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies are not eligible.
  • Age 18 years of age and older.

Must meet required laboratory values. 

Enrollment: 500 patients will be enrolled

Benefits:

Taking part in this study may or may not make your health better.  While doctors hope adding bevacizumab to gemcitabine and cisplatin will be more useful against cancer compared to gemcitabine and cisplatin alone, there is no proof of this yet.  We do know that the information from this study will help doctors learn more about these drugs as a treatment for cancer.  This information could help future cancer patients.

Contact:

These clinical trial overviews are intended to provide a brief overview of the clinical trial. To help determine whether the trial is appropriate for you, the major eligibility criteria are listed above. To obtain more information on the eligibility and the treatment plan, please contact our Aspirus Regional Cancer Center Oncology Clinical Research Coordinator, Beth Knetter at 715-847-2353 or 1-800-283-2881, ext.72353, or Langlade Cancer Center Research Nurse Debra Witman @ 715-623-9587.

Created: Feb 24, 2014

Updated: Oct 16, 2014

« Return to Trials